Rehabilitation of Malnourished Infants With F-100 or Diluted F-100

Rehabilitation of Severely Malnourished Infants Aged <6months: a Randomised, Controlled Comparison of Three Recovery Diets (Infant Formula, F-100 and Diluted F-100)

Hypothesis:

During rehabilitation phase of management of severe acute malnourished Bangladeshi infants less than 6 months old, rates of weight gain will be significantly more in children fed F-100 and diluted F-100 compared to those fed infant formula.

Brief summary:

Until recently, severe malnutrition has been relatively rare in infants younger than 6 months, but with urbanization and the HIV/AIDS pandemic it is feared that the incidence of severe malnutrition among young infants will rise. The question of how best to feed infants aged <6 months has thus come to the forefront. Given the lack of published evidence regarding the most advantageous formulations for feeding severely malnourished infants aged <6 months, there is a need for observational studies and comparative randomized trials of alternative formulations to guide decisions about optimum dietary management in this age group. This area has been aptly considered a research priority during the consultation meeting of experts from all over the world convened by the World Health Organization on management of severe malnutrition in September 2004.

In the WHO case-management guidelines for severe malnutrition, there is no separate provision for young infants (infants less than 6 months old). The guidelines suggest the use of a low-solute formula (F-75) and continued breastfeeding in the initial stabilisation phase. In the rehabilitation phase, the guidelines advise F-100 with an energy density of 100kcal/100ml to promote catch-up growth. There is a concern that the renal solute load from using F-100 is too high for young infants, and some groups have started using diluted F-100 with an energy density of 75 kcal/100 ml.

Another related issue is the contribution of breastfeeding in dietary intakes during rehabilitation. In severely malnourished infants, breast milk intakes are likely to be low initially when appetite is poor, but may be substantial as the infant recovers. Uncertainty about breast milk intakes has led to conflicting opinions and advice, weaning from the breast as it is not providing sufficient energy (1).

The aim of this study, to be conducted in a carefully supervised Nutrition Rehabilitation Unit (NRU), will compare three recovery diets (Infant formula, F-100 and diluted F-100) in order to provide the evidence-base to determine if a change or add-on in terms of diet in the WHO guidelines is needed. It will also measure the potential renal solute load (mosmol/l), serum electrolytes and plasma osmolality of the same children. Body composition of the infants will also be measured using stable isotope dilution technique before and after the intervention diet is provided.

Study Overview

Detailed Description

Study design: This is a randomized controlled trial comparing three recovery diets and will be conducted at a Nutrition Rehabilitation Unit (NRU).

Duration of the study: 24 months. Study site: The trial will take place at the Dhaka Hospital of ICDDR, Bangladesh. This hospital has a high case load, peaking during April-October, and the WHO guidelines for the management of severely malnourished children with minor modifications are followed. Diarrhoea is the entry point for all patients attending the hospital including children.

Methods During the stabilization phase or the acute phase management, children will be fed every 2 hourly with 130ml/kg/day F-75 along with other necessary management according to WHO guidelines (8). Judgment regarding suitability for transfer to the rehabilitation phase will be made by the regular doctors at the longer-stay ward according to set criteria: i) return of appetite (i.e. hungry, easily finishes a feed), ii) naso-gastric feeding is not required, iii) absent or insignificant oedema, iv) cessation of vomiting, v) less than 3 watery stools/day, and vi) no clinical signs of infection.

When ready for the rehabilitation phase, eligible children will be transferred to the NRU and randomized to receive any of the three diets (Infant formula, F-100 or diluted F-100). For the first 2 days on the test diets, they will be fed 130ml/kg/day in 12 (2-hourly) feeds and then 10ml more at each feed until some is left. This is equivalent to the transition phase in the WHO guidelines. During these 2 days the infants' pulse and respiration rates will be monitored 3 hourly to find out the signs of possible fluid overload. Thereafter they will be fed at 3 hour intervals. Infants will be fed by trained research personnel and will be encouraged to eat until full. Being 'full' will be defined as two successive refusals when feed is re-offered. Water will be freely available between feeds. Breastfed children will continue to be breastfed. Pulse and respiration rates and temperature will be monitored every 8 hours. If, any of the infants shows the signs of fluid overload, they will be transferred to longer-stay or special care ward and will be managed according to the standardized management protocol practiced at Dhaka Hospital of ICDDR,B.

All the children who are accompanied by mothers will be counselled by professional breastfeeding counsellor for relactation if the child is already weaned from the breast.

Measurement of the diets: All feeding episodes will take place under the supervision of study personnel. Food portions will be weighed before and after serving using an electronic balance with one-gram precision, and the actual amount consumed will be calculated by subtracting leftover food from the amount offered. Pre-weighed napkins will be provided; any food that is regurgitated, vomited or spilled will be swabbed, weighed and subtracted from the amount offered.

Measurement of breast milk intake: If, the particular child is breastfed or the re-lactation has been established, then the mothers will be requested to breastfeed day and night, according to the usual feeding pattern at home prior to the study or if the child demands. At each nursing, breast milk will be offered until the child refuses further intake, and the amount consumed will be measured by test-weighing before and after nursing, while ensuring that the child wears the same clothing for each weighing. Each nursing episode initiated after taking a post-feeding weight will be considered a new episode, and the intake will be similarly measured. Breast milk intake will be measured by recording the difference in the child's weight before and after the feed, using an electronic balance with two-gram precision, and the weight change will be adjusted for child-specific insensible losses, which will be measured on the same balance for at least 30 minutes each day. The duration of each episode of breast-feeding will be measured using a stopwatch, and the duration and frequency of breastfeeding in 24 hours will also be recorded.

Discharge criteria: Body weight gain 15% of the admission bodyweight or as soon as the infant becomes oedema free or if the child has an oedema free weight-for-length Z-score ≥ 2.

Follow-up: At the time of discharge, the mother/caregiver will be asked to bring his/her child to the nutritional follow-up unit after 2 weeks, then monthly for 3 months. In every visit the child will be measured for weight, height and mid-upper arm circumference and will also be examined for any possible illness(s). If, any of the child fails to come for scheduled follow-up, study personnel will visit their respective homes to know the well-being and status of the subjects.

Deuterium Oxide Dilution Technique for the Assessment of Body composition:

The following procedure for assessment of body composition will be conducted on the day the infant will be transferred to the NRU and repeated at the time of discharge.

Deuterium oxide (2H2O) will be used for body composition assessment. Upon enrolment, baseline saliva samples will be collected. After collection of baseline saliva samples 5g of deuterium oxide labelled water will be fed to the study infant. Children should avoid drinking water during the equilibration period, i.e., 3-4 hours after ingestion of the stable isotope dose. According to the recommendation from International atomic Energy Agency (IAEA) field manual (9), two post-dose saliva samples will be collected at 3rd and 4th hours. The concentration of deuterium oxide in saliva samples will be measured with Fourier Transform Infrared Spectrometer (FTIR) and for total body water (TBW) estimation. Afterward from measured TBW, the amount of fat free mass (FFM) can be estimated. Body fat mass (FM) is the difference between body weight and fat free mass (10).

Therefore for each child, saliva samples will be collected 6 times (2 baseline and 4 post dose) during the course of NRU stay.

Calculation of body composition:

The dilution space of 2H (VD) is 4.1 % higher than TBW due to exchange of H with non-aqueous H in the body TBW (kg) = VD /1.041 Where, VD (kg) = Dose 2H2O (mg)/enrichment 2H in saliva (mg/kg) FFM (kg) = TBW (kg) / hydration coefficient*

  • Hydration factor = Hydration of FFM (%FFM)/100 Fat mass (FM) is calculated by difference between body weight and FFM FM (kg) = body weight (kg) - FFM (kg) Results are often expressed as % body weight FM (%) = FM (kg) / body weight (kg) x 100
  • Please see Table 2; Hydration factor for children (11, 12) Randomization After assessing suitable for initiating the rehabilitation phase, infants will be randomized to the test diets in blocks of 6 using a random numbers table (EPI-INFO 6.04, CDC Atlanta, GA). Allocation will be concealed in sealed envelopes. The codes will be kept secure and not broken until data analysis is complete. Medical and nursing staff and the children's carers will be blind as to the formula given. Infant formula, F-100 and diluted F-100 will be similar as much as possible in appearance and will be prepared by the dietician. The invitation to participate in the research will be given at admission before randomization.

Data collection

  1. Rate of weight gain (g/kg/day):

    Body weight will be measured daily with a digital scale, precision 2g.

    Calculation of weight gain (13,14,15):

    Weight gain in g/kg.day = (W2 - W1) x 1000/(W1 x number of days from W1 to W2)

    Where:

    • W1 = lowest weight during the NRW stay in kg (usually the 1st day of NRW-weight in case of marasmic children, but it may vary in case of oedematous children)
    • W2 = weight in kg on the day of calculation
  2. Intake (kcal/kg/day):

    During the stay at NRU, amounts of the test diets offered and eaten, and water consumed, will be recorded by the research assistants.

  3. Renal solute load (mOsmol/l):

    Potential renal solute load: PRSL = N/28 + Na + C1 + K + Pa Where, N= Nitrogen content of the diet (mg/28=mosm) Na= Sodium content of the diet (mg/23=mosm) Cl= Sodium content of the diet (mg/35=mosm) K= Potassium content of the diet (mg/39=mosm) Pa= Available Phosphorous content of the diet (mg/31=mosm)

    0.9 mOsm of PRSL are retained per gram of weight gain (4). RSL will, therefore, be estimated using the equation: RSL est = PRSL - (0.9 x gain) Where: RSL est and PRSL are expressed as mOsmoles per day and gain is weight gain in grams per day (7).

  4. Serum sodium and plasma osmolality:

    Two ml blood will be taken from antecubital vein of the child on days 1, 3, and 7 for measuring serum sodium, potassium, chloride, total carbon dioxide, creatinine and osmolality. This will allow monitoring of osmolar state of the child i.e. hypernatremia. Spot urine samples on the above mentioned days will be checked for specific gravity and osmolality/creatinine ratio. Urine will be collected in paediatric urine collector bags. Standard methods will be used for measuring electrolytes, creatinine, osmolality and specific gravity in the Clinical Biochemistry Laboratory of ICDDR,B.

  5. Extra-renal water losses: Loss of body fluids due to diarrhoea and vomiting will be recorded, as will fever, environmental temperature and humidity.

Outcome measures:

  1. Rate of weight gain (g/kg/day)
  2. Food Intake (kcal/kg/day)
  3. Breast milk intake (if the child is breastfed) (g/kg/d) and (kcal/kg/d)
  4. Renal solute load (mOsmol/l):

Sample size estimation:

In NRU of Dhaka Hospital of ICDDR,B, 124 children suffering from SAM who were managed with infant formula along with other recommended WHO-guidelines had a daily mean ± SD weight gain of 10.25 ± 6.7 g/kg/day. If, we assume that with F-100 or diluted F-100 the rate of weight gain will be 15 g/kg/d, then we require 40 children in each group with 80% power and 5% level of significance. If, the investigators further consider 10% attrition then each group will require 44 infants. So, the investigators will study 44 infant in each group giving a total of 132 children in three study groups.

data Analysis: All recording forms will be pre-coded and checked daily for completeness and consistency. Differences among the groups will be assessed using chi-squared tests for proportions and analysis of variance (ANOVA) for normally-distributed continuous variables. Paired t-test for paired comparison before and after the intervention will be performed. The analysis will be on an intention-to-treat basis. Statistical analysis will be with the Statistical Package for the Social Sciences, version 11.5 for Windows (SPSS Inc, Chicago, Ill). Subgroup analyses will be conducted to test if age has a differential effect on renal solute load among the groups.

Study Type

Interventional

Enrollment (Actual)

132

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Dhaka
      • Dhaka, Mohakhali, Dhaka, Bangladesh, 1212
        • Icddr,b

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 6 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • They have a weight-for-length deficit of <-3SD and/or bi-pedal oedema on admission
  • They are less than 6 months old and have completed the initial stabilization phase
  • They are stabilized in less than 9 days (to exclude children who fail to respond to treatment)
  • Parental consent is obtained for enrollment in the study.

Exclusion Criteria:

  • Infants with congenital anomalies such as, congenital cardiac defects, cleft lip or palate or any other condition that interfering with feeding, chromosomal anomalies, and other organic problems including jaundice, tuberculosis etc. will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Infant Formula
A diet that is being fed to the young infants
A diet that is being fed to the young infants.
Experimental: F-100
• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
Experimental: Diluted F-100
300 ml of water is added to 1000 ml of F-100
300 ml of water is added to 1000 ml of f-100

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
rate of weight gain (g/kg/d)
Time Frame: Duration of the hospital stay when the study participants will fulfill the discharge criteria. On an average of 2 weeks.
Duration of the hospital stay when the study participants will fulfill the discharge criteria. On an average of 2 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Md. Munirul Islam, MBBS, PhD, Associate Scientist

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (Actual)

June 1, 2015

Study Completion (Actual)

June 1, 2015

Study Registration Dates

First Submitted

March 5, 2012

First Submitted That Met QC Criteria

March 17, 2012

First Posted (Estimate)

March 20, 2012

Study Record Updates

Last Update Posted (Estimate)

July 28, 2015

Last Update Submitted That Met QC Criteria

July 26, 2015

Last Verified

June 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PR-10039

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infant Formula

3
Subscribe